Zur Kurzanzeige

dc.contributor.authorLavado Fernández, Elena
dc.contributor.authorPérez Montes, Cristina
dc.contributor.authorRobles García, Miguel 
dc.contributor.authorSantos Ledo, Adrián 
dc.contributor.authorGarcía Macia, Marina 
dc.date.accessioned2026-02-10T08:35:23Z
dc.date.available2026-02-10T08:35:23Z
dc.date.issued2026-01-03
dc.identifier.citationLavado-Fernández, E., Pérez-Montes, C., Robles-García, M., Santos-Ledo, A., y García-Macia, M. (2026). Melatonin at the crossroads of oxidative stress, immunity, and cancer therapy. Antioxidants, 15(1), 64. https://doi.org/10.3390/antiox15010064
dc.identifier.urihttp://hdl.handle.net/10366/169673
dc.description.abstract[EN] Melatonin, an ancient and evolutionarily conserved indolamine, has long attracted attention for its multifunctional roles in redox homeostasis. More recently, it has been studied in relation to immune regulation and cancer biology. Beyond its well-known circadian function, melatonin modulates oxidative stress by directly scavenging reactive oxygen and nitrogen species and by upregulating antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase. At the same time, it exerts wide-ranging immunomodulatory functions by influencing both innate and adaptive immune responses. All these actions converge within the tumor microenvironment, where oxidative stress and immune suppression drive cancer progression. Although the antitumoral effects of melatonin have traditionally been interpreted through its actions on T cells and NK cells, recent studies identify macrophages as an underappreciated and pivotal target. Notably, melatonin influences macrophage polarization, favoring antitumor M1 phenotypes over pro-tumoral M2 states, while attenuating chronic inflammation and restoring mitochondrial function. This review summarizes current knowledge on melatonin’s antioxidant and immunoregulatory mechanisms, highlighting its impact on the tumor immune microenvironment, with a particular focus on the growing recognition of macrophages as a compelling new axis through which melatonin may exert anticancer effectses_ES
dc.description.sponsorshipFunding text E.L.-F. has an FPI contract (PRE2023-138478) funded by the grant PID2022-138478OA-100. C.P.-M. has a contract from the Plan Especial Grado Medicina (USAL), A.S.-L research is funded by the Lanzadera TCUE and C2 program (Universidad de Salamanca); and M.G.-M. is a Ram\u00F3n y Cajal researcher (grant RYC2021-033684-I, funded by MICIU/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR), and her research is funded by the PID2022-138478OA-100, funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE.es_ES
dc.description.sponsorshipE.L.-F. has an FPI contract (PRE2023-138478) funded by the grant PID2022-138478OA-100. C.P.-M. has a contract from the Plan Especial Grado Medicina (USAL), A.S.-L research is funded by the Lanzadera TCUE and C2 program (Universidad de Salamanca); and M.G.-M. is a Ramón y Cajal researcher (grant RYC2021-033684-I, funded by MICIU/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR), and her research is funded by the PID2022-138478OA- 100, funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE.
dc.format.mimetypeapplicatio/pdf
dc.language.isoenges_ES
dc.publisherMDPI
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectAntioxidantses_ES
dc.subjectCancer therapyes_ES
dc.subjectImmune modulationes_ES
dc.subjectMacrophageses_ES
dc.subjectMelatonines_ES
dc.subjectOxidative stresses_ES
dc.subjectTumor microenvironmentes_ES
dc.titleMelatonin at the Crossroads of Oxidative Stress, Immunity, and Cancer Therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/antiox15010064
dc.subject.unesco2302.15 Hormonas
dc.subject.unesco2412 Inmunología
dc.identifier.doi10.3390/antiox15010064
dc.relation.projectIDPRE2023-138478es_ES
dc.relation.projectIDPID2022-138478OA-100es_ES
dc.relation.projectIDRYC2021-033684-Ies_ES
dc.relation.projectIDMICIU/AEI/10.13039/501100011033es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn2076-3921
dc.journal.titleAntioxidantses_ES
dc.volume.number15es_ES
dc.issue.number1es_ES
dc.page.initial64es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution 4.0 International
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution 4.0 International